This site is intended for healthcare professionals only

New test to reliably predict spread of skin cancer

Written by: | Published:

Melanoma is increasing worldwide Melanoma is increasing worldwide

A new test that reliably predicts the spread or return of the deadliest form of skin cancer has been developed by scientists working with the University of Newcastle.

The test identifies a patient’s true risk of disease progression and provides anyone diagnosed with a non-ulcerated early-stage melanoma - accounting for around 75% of all new diagnoses - more accurate information about the risk of the disease spreading. Melanoma is increasing worldwide and every year more than 16,000 people in the UK and 96,000 people in the US are diagnosed with the cancer.

Read more: New campaign launched urging pregnant women to get boosted

‘Like mortar and bricks holding together a wall, AMBRA1, Loricrin and Claudin 1 are all proteins key to maintaining the integrity of the upper layer of the skin,’ said Senior author Professor Penny Lovat, Professor of Cellular Dermatology and Oncology at Newcastle University.

‘When these proteins are lost gaps develop – like the mortar crumbling away in the wall. This allows the tumour to spread and ultimately ulcerate which we know is a process associated with higher risk tumours. Our new understanding of this biological mechanism underpins the test we have available.’

Read more: Need for improvements to children’s diets after pandemic

In the research, published in the British Journal of Dermatology, the authors explain how early-stage melanomas at risk of spreading secrete a growth factor, which causes the reduction, or downregulation, of the proteins AMBRA1 and Loricrin, both of which are found in the skin overlaying the tumour. The growth factor also causes the loss of claudin-1 leading to loss of the integrity of the skin and facilitating ulceration.

‘This is excellent news,’ said Professor Nick Levell, Consultant Dermatologist and British Skin Foundation spokesperson. ‘This new test for melanoma will help many people with skin cancer. People at low risk can be reassured and will not have to attend hospital so often for check-ups. This British Skin Foundation co-funded research is an important step forward in making care after melanoma more personal.’

What do you think? Leave a comment below or tweet your views to @IndyNurseMag

This material is protected by MA Healthcare Ltd copyright.
See Terms and Conditions.



Please view our Terms and Conditions before leaving a comment.

Change the CAPTCHA codeSpeak the CAPTCHA code

Read a free issue from Practice Nursing

Register to read a free issue from our sister publication, Practice Nursing.

Including articles on asthma, diabetes and more. Read your copy.


Sign up to the newsletter


Independent Nurse is the professional resource for primary care and community nurses, providing clinical articles for practice nurses and prescribers.


Subscribe to our newsletter and stay up to date with the latest nursing news.

Stay Connected

Stay social with Independent Nurse by following us on Twitter, liking us on Facebook or connecting on LinkedIn.


Need access to some of our older articles? You can view our archive, or alternatively contact us.

Contact Us

MA Healthcare Ltd.
St Jude's Church, Dulwich Road
London, SE24 0PB

Tel: +44 (0)20 7738 5454
Registered in England and Wales No. 01878373

Meet the team


Find out how to contribute to Independent Nurse here.